Insulin pumps have most reported problems in FDA database Empagliflozin improves survival in type 2 diabetes patients with established cardiovascular diseaseEstimated to improve life expectancy by one to 4.5 years according to an analysis of data from a major trial Pharmacologic management of type 2 diabetes New developments in type 2 diabetes care Montreal diabetes prevention clinic said to be first of its kind in Canada Study examines risk of serious adverse events with SGLT2 inhibitors in type 2 diabetes Finds twofold increases in the risk of lower limb amputation and diabetic ketoacidosis 2018 Consolidated Canadian guideline for preventing and managing cardiovascular disease in primary care C-CHANGE guideline combines recommendations from nine Canadian cardiovascular-related guidelines to meet primary care needs Pharmacist pushes for free access to insulin pen needles in Ontario In a quest to get insulin pen needles covered under Ontario’s provincial drug plan, one pharmacist is taking matters into her own hands. Combination therapy safe and effective in older type 2 diabetes patients New study examines 'real-world' safety and efficacy of GLP-1 agonist and SGLT-2 inhibitor combo when used in elderly patients with suboptimal glycemic control Second basal insulin/GLP-1 agonist combo for type 2 diabetes now available Glargine–lixisenatide combo joins degludec–liraglutide combo on Canadian market First Previous 22 23 24 25 26 Next Last
